Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial

German Atrial Fibrillation Network0 个研究点目标入组 422 人开始时间: 2005年10月4日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Documented paroxysmal atrial fibrillation: electrocardiogram (ECG) documentation of atrial fibrillation at least
•in one ECG recorded during the last 2 months prior to randomization plus additional ECG recording of sinus rhythm at least 12 hours after the above mentioned ECG documentation
•2. Age =18
•3. Patient informed orally and in writing
•4. Written informed consent of the patient

•1. Strong clinical evidence for therapy with AT II/ACE inhibitors within the last month
•2. Therapy with antiarrhythmic agents of class I or class III within the last month, therapy with amiodaron within the last 3 months
•3. DC cardioversion within the last 3 months
•4. Symptomatic bradycardia
•5. Implanted pacemaker or implanted cardioverter/defibrillator with any antitachycardiac algorithm in use
•6. Cardiac surgery or cardiac catheter ablation within the last 3 months
•7. Typical angina pectoris symptoms at rest or during exercise
•8. Known coronary artery disease with indication for intervention
•9. Valvular disease >II degree
•10. Left ventricular ejection fraction <40%
•11. Diastolic blood pressure >110 mmHg at rest
•12. Symptomatic arterial hypotension
•13. Known renal artery stenosis
•14. Serum creatinine >1.8 mval/l

发起方

German Atrial Fibrillation Network